ArticleFrontiers in ophthalmology2026
Two-year outcomes of PRESERFLO MicroShunt implantation in a real-world heterogeneous glaucoma cohort: a retrospective single-center study.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate intraocular pressure (IOP), medication burden, best-corrected visual acuity (BCVA), and safety outcomes after Methods: This retrospective single-center study included patients undergoing PreserFlo implantation (standalone or combined with phacoemulsification) between 2019 and 2022. IOP, BCVA, and glaucoma medications were collected preoperatively and postoperatively (day 1, week 1, month 1, year 1, and year 2). Hypotony was defined as IOP ≤ 5 mmHg. Complete success at 2 years required IOP ≤ 21 mmHg with ≥20% reduction from baseline without glaucoma medication. Results: Eighty-one eyes of 74 patients (mean age 73.2 years) were included. Mean baseline IOP was 24.0 ± 10.2 mmHg, decreasing to 12.5 ± 3.8 mmHg at year 1 (p < 0.0001) and 13.5 ± 3.4 mmHg at year 2 (p = 0.0005). Mean BCVA was 0.63 ± 0.30 at baseline, 0.70 ± 0.31 at year 1, and 0.73 ± 0.27 at year 2, indicating stable visual acuity during follow-up. Mean IOP reduction was 39.6% at year 1 and 33.8% at year 2; 75.6% and 73.3% achieved ≥20% IOP reduction at years 1 and 2, respectively. Medications decreased from 3.09 ± 1.02 to 0.44 ± 0.97 (year 1) and 0.45 ± 0.85 (year 2), and their medication-free rates were 80.5% and 73.3%, respectively. Complications occurred in 55.6% of eyes; 27.2% required postoperative interventions (needling 20.9%); 15.0% required further glaucoma surgery. Complete success rates were 60.2% (year 1) and 52.0% (year 2). Conclusions: PreserFlo implantation provided sustained mid-term IOP reduction with substantial medication sparing and stable BCVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.